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Body size, as measured by height in humans or weight in 
domestic species, is an archetypical quantitative or com­
plex trait that shows continuous variation. It has been 
extensively recorded and studied for over a century 
because of its importance to ecology, its relevance in 
farming, and because it is an important indicator of 
human growth and health [1]. The genetic architecture 
underlying body size was initially uncertain and Fisher 
proposed an infinitesimal model that was successfully 
applied for many years [2]. This model, with an infinite 
number of loci, each with infinitesimal effect, is not 
literally true but it does provide a good fit to the data. In 
more recent times the infinitesimal model has gradually 
been replaced by a finite number of loci, each with 
discrete mutations. However, observations now form 
almost two disjointed sets: one set in which individual 
mutations have large effects (that is, so­called Mendelian 
traits) and another set where variants have small effects. 
This review attempts to bridge the gap between these two 
sets of observations using body size as an example of an 
extensively studied complex trait in mammalian species.
The genetic architecture underlying variation in 
complex traits is currently a topic of extensive debate. 
This is particularly true for human complex diseases but 
also for agriculture because of its impact in predicting 
future phenotypes (for example, [3­6]). Primarily it is the 
number, size and frequency of mutations that are under 
the most scrutiny. Taking the human disease example, 
some argue for a common disease common variant 
hypothesis where genetic susceptibility to disease is the 
result of many relatively high­frequency mutations each 
with small effect on disease susceptibility. However, 
others argue for a rare variant common disease hypo­
thesis where many low­frequency mutations have large 
effects. As we shall see, observations on the genetic 
architecture underlying body size for humans and other 
mammals provide evidence for both hypotheses. Our 
discussion begins by describing the number, frequency 
and size of mutations with large effects for humans, mice 
and domesticated species. We then move onto genome­
wide association studies (GWASs) that have investigated 
segregating variation in these species. We find evidence 
for moderate­to­large effect mutations in domestic 
species but highlight that this category of mutations goes 
undetected in human studies. Finally, we apply simple 
evolutionary theory to explain the observed distribution 
of mutation effects for human stature. Our model implies 
that most of the segregating variation in human height is 
caused by mutations with small­to­moderate effects.
Variants of large effect
Family studies in humans
Identification of causative mutations for so­called Men­
delian traits has been possible by studying the segregation 
within families of mutations and phenotypes. Such 
mutations must have large effects so that individuals can 
be classified into genotype classes using their phenotype 
despite the background variation caused by other genes 
and environmental effects. Abnormal stature, for exam­
ple, is generally diagnosed by clinicians when individuals 
are greater than ±2  standard deviation (SD) units from 
the population average. A recent survey of Mendelian 
traits causing aberrant stature and other obvious skeletal 
abnormalities in humans revealed the involvement of at 
least 241 genes [7].
Details for a sample of ten Mendelian disorders are 
given in Table  1. The overwhelming observation is that 
many conditions affect stature, and extensive details are 
available for even the rarest of conditions. In effect, 
modern healthcare systems have provided an efficient 
global screen for human mutations [8]. Despite the com­
plexities, some similarities between Mendelian disorders 
can be observed, and these include the following: 
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Table 1. Genetic properties and complexities of ten conditions reported in humans with short or tall stature phenotypes 
(cases represent a cross-section of rare and extremely rare disorders)
  Stature  Hetero- 
Syndrome Gene effecta Inheritanceb geneity Notes References
Marfan syndrome 
(OMIM 154700)
FBN1 (fibrillin 1) +2.2  
SD
Autosomal dominant; 
25% de novo mutations; 
prevalence of 2 to 3 
in 10,000 live births; 
most alleles exhibit 
haploinsufficiency (where 
the product from a single 
functional copy of the gene 
is insufficient for normal 
function)
>500 
mutations
FBN1 is a very large (>600 kb) and highly 
fragmented (65 exons) gene; phenotypic 
heterogeneity and a spectrum of Marfan-like 
disorders suggest involvement of other 
genes; mutations in the functionally related 
transforming growth factor-β receptor, 
type II gene (TGFBR2) is also known to 
cause Marfan syndrome; symptoms include 
disproportionate overgrowth of limbs, and 
ocular and cardiovascular abnormalities
[10,37-47]
Sotos syndrome 
(OMIM 17550)
NSD1 (nuclear 
receptor binding 
SET domain protein 
1)
+2  
SD
Autosomal dominant; 95% 
de novo mutations; 1 in 
14,000 live births
>100 
mutations
NSD1 mutations in 80% to 90% of cases; 
symptoms include characteristic facial 
features, overgrowth and mild-to-severe 
learning disabilities with possible cardiac, 
dental and renal abnormalities; increased 
tumor risk
[48-50]
Beals syndrome 
(OMIM 121050)
FBN2 (fibrillin 2) +2  
SD
Autosomal dominant; rare; 
mostly inherited
10  
mutations
Similar phenotype to Marfan syndrome 
but with fewer complications; FBN2 
abnormalities in 27% to 70% of cases; 
probable involvement of other loci; reports 
of a lethal mutation and somatic/germline 
mosaicism
[51-54]
3M syndrome 
(OMIM 273750)
CUL7 (cullin 7) -5.6  
SD
Autosomal recessive; 
very rare, 40 to 50 cases 
reported
>45  
mutations
Mutations in OBSL1 and CCDC8 can also 
cause 3M syndrome; symptoms include 
severe prenatal and postnatal growth 
retardation, characteristic facial features and 
normal intelligence
[55-59]
Costello 
syndrome (OMIM 
218040)
HRAS (v-Ha-ras 
Harvey rat sarcoma 
viral oncogene 
homolog)
-5  
SD
Autosomal dominant; 
mostly de novo mutations; 
very rare, 250 cases 
worldwide
>10  
mutations
Recurrent missense mutation in HRAS 
reported in up to 80% of cases; somatic/
germline mosaicism confirmed in one case 
and suspected in others; symptoms include 
postnatal failure to thrive, intellectual 
disability, coarse facial features, cardiac 
abnormalities and an increased risk of 
malignant tumors
[60-63] 
Achondroplasia 
(OMIM 100800)
FGFR3 (fibroblast 
growth factor 
receptor 3)
-5  
SD
Autosomal dominant; 80% 
de novo mutations; 0.5 to 
1.5 in 10,000 live births
>10  
mutations
Most common form of dwarfism; 97% of 
cases show one of two mutations that cause 
a missense glycine to arginine substitution 
at position 380 in FGFR3; missense mutation 
associated with gain-of-function and 
overactivation of negative growth control; 
evidence for increasing prevalence with 
increasing paternal age; other mutations 
in FGFR3 implicated in other diseases 
(including more severe skeletal dysplasias); 
symptoms include shortened limbs 
and facial features; unexplainably high 
prevalence and de novo mutations suggest 
other factors (such as positive selection of 
sperm) may influence the prevalence of the 
disease
[11,64-72]
Cornelia de Lange 
syndrome (OMIM 
122470)
NIPBL (nipped-B 
homolog) 
(Drosophila)
-2  
SD
Autosomal dominant; 
mostly de novo mutations; 
1 in 10,000 to 1 in 30,000 
live births
>80  
mutations
NIPBL abnormalities reported in 60% of 
cases; mutations of SMC1A (X-linked) and 
SMC3 in <6% of cases; maybe involvement 
of other loci; germline mosaicism 
implicated; phenotypic heterogeneity, 
including characteristic facial features, 
postnatal growth retardation, hirsutism 
and possible oligodactyly (missing digits); 
symptoms may approach non-syndromic 
mental retardation
[73-77]
Continued overleaf
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(1) Most mutations confer a range of clinical symptoms 
caused by pleiotropic effects of the mutation. For 
instance, Cornelia de Lange syndrome can cause growth 
failure and profound intellectual disability [9]. Pleiotropy 
is also a common feature for a range of other human 
diseases [10]. (2)  The syndromes have a very low 
prevalence and de novo mutations often account for a 
substantial portion of this incidence. (3)  Most of the 
conditions show extensive allelic heterogeneity. For 
example, a prevalence (in the order) of 1 in 10,000 births 
and a 25% de novo mutation rate for Marfan syndrome 
(Table 1) suggests, assuming a mutation rate per base of 
10­8 per generation, that there may be up to 2,500 possible 
mutable positions in genes causing Marfan­like pheno­
types (that is, 0.25  × 1  × 10­4/1  × 10­8  = 2,500 mutable 
positions, equivalent to approximately 1% of bases in 
FBN1). (4)  Different mutations within a particular gene 
may be associated with different (related) clinical diseases 
or different degrees of severity for a single disease. For 
example, the type of missense mutation in the lysine 
codon at position 650 (Lys650) in FGFR3 determines the 
relatively mild hypocondroplasia (Lys650Asn/Gln) or the 
more severe conditions of SADDAN (severe achondro­
plasia with developmental delay and acanthosis nigricans) 
or thanatophoric dysplasias (Lys650Glu/Met) [11]. 
Similarly in Marfan syndrome, patients with a premature 
stop codon or mutations in exons 24 to 32 of FBN1 have 
more severe symptoms than those with inframe muta­
tions or mutations at different locations [12]. Potentially 
more disruptive mutations and those in highly conserved 
regions lead to increased clinical severity of the pheno­
type [13]. (5)  Both dominant and recessive mutations 
affect stature and these do not correlate perfectly with 
gain or loss of function for the gene. (6) Known mutations 
often cannot account for all cases of a particular disease. 
Usually other genes, presumably with a functional 
relation ship to the known loci, are thought to be involved. 
(7)  There are more mutations causing a reduction in 
height than those causing an increase.
Mutations in laboratory mice with large effects
Spontaneous and chemically induced mutations affecting 
size have been reported in mice. As with family studies in 
humans, the effect of the mutation needs to be large 
(>3 SD) to be recognized, and the causative gene identi­
fied and reported [14]. These approaches probably miss 
loci where the mutations have more subtle effects [15]. 
Despite this, spontaneous and chemically induced screens 
have been successful in identifying over 500 genes asso­
ciated with abnormal postnatal growth or body size [16]. 
By comparison, this is more than twice the number of 
loci identified in humans.
Allelic heterogeneity is not a feature of the mouse 
mutations as it is in humans, because relatively few alleles 
Growth hormone 
insensitivity 
syndrome (GHIS) 
(OMIM 262500)
GHR (growth 
hormone receptor)
-7 to  
-3.6  
SD
Mostly autosomal recessive; 
rare, 100 to 200 cases 
reported worldwide mostly 
in two large cohorts
>50  
mutations
Biochemical and clinical heterogeneity; 
most severe form (Laron syndrome, effect -7 
SD) to partial growth hormone insensitivity 
(-3.6 SD); one case of autosomal dominant 
inheritance; probable involvement of 
other loci as no abnormalities in GHR 
detected in some patients; symptoms may 
include severe postnatal growth failure, 
underdeveloped facial bones and slow 
motor development
[78-81]
Geleophysic 
dysplasia (OMIM 
231050)
ADAMTSL2 
(ADAMTS-like 2)
-4.5  
SD
Autosomal recessive; very 
rare, 31 reported cases
>5  
mutations
Very similar to Weill-Marchesani syndrome 
and acromicric dysplasia; missense and 
nonsense mutations detected in 70% of 
individuals; possible involvement of other 
genes; high early childhood mortality 
(33%) resulting from cardiac and respiratory 
dysfunctions
[82,83]
Hypochrondro- 
plasia (OMIM 
146000)
FGFR3 (fibroblast 
growth factor 
receptor 3)
-3.2  
SD
Autosomal dominant; 
assumed mostly de novo 
mutations with prevalence 
similar to achondroplasia 
(that is, 1 in 15,000 to 1 in 
40,000 births) 
>10  
mutations
Sever hypochondroplasia is similar to mild 
achondroplasia; most hypochondroplasia 
cases are associated with alanine-for-
asparagine substitution in exon 10 of FGFR3; 
other mutations account for <2% of cases; 
suspected involvement of other loci for 
milder forms of the disorder
[84-86]
aApproximate effect in standard deviation (SD) units; either the mid-point of the SD range or the mid-point of adult height converted to SD units (assuming mean 
height 174 cm and SD 7 cm, Australian Bureau of Statistics [61]); when there was no attempt to quantify ‘short’ or ‘tall’ stature effect size is assumed to be ±2 SD; bfor 
cases reported as rare, the assumed frequency rate is 1/100,000 births. kb, kilobase; OMIM, Online Mendelian Inheritance in Man [87].
Table 1. Continued
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are sampled in the small numbers of inbred lines typically 
used. Similarly, the identification methods also bias the 
observed inheritance patterns for mutations. Thus, many 
of the spontaneous mutations initially identified, such as 
little, pygmy or Ames dwarf, are recessive [16,17], where­
as the chemically induced mutagenesis screens tend to 
identify dominant, rather than recessive, alleles [14]. 
These idiosyncrasies relate to identification methods, 
because of inbreeding strategies or the efficiencies for 
detecting dominant phenotypes, rather than biological 
characteristics.
Gene knockout in mice
The direct manipulation of the mouse genome via gene 
knockout technology implicates genes in growth and 
development by inducing a loss­of­function mutation at 
specific loci. This is advantageous because both viable 
and non­viable mutations are represented, but limited 
because genes must be specifically targeted for knockout 
candidates. Surveying only viable mutants, Reed et al. 
[18] extrapolate from reported knockout lines to estimate 
approximately 6,000 genes may cause either ‘lighter and 
smaller’ or ‘larger and heavier’ body size in mice (that is, 
25% of the estimated total number of genes in mam­
malian genomes [19]). Reed et al. did not attempt to 
define the size of effect for each locus [18], but presu­
mably effects were large because they were readily 
noticeable. The estimate of 6,000 genes may also be an 
under estimate of the number of loci influencing body 
size because of the lethality for some knockouts of genes 
known to affect body size in other mammals (for 
example, FGF4; Table 2). Reed et al. observed that nulli­
fying genes caused about ten times as many small body 
size phenotypes compared with large body size 
phenotypes, similar to natural mutations in humans [18]. 
These observations support the hypothesis that the 
genome is biased towards a larger rather than smaller 
body size [18,20].
Mutations of large effect in domestic species
Only a handful of causative mutations affecting body size 
in domestic livestock and companion species have been 
identified (Table  2). Six of the seven genes also have 
mutations with large effect for body size in mice and/or 
humans. Most of the mutations have been identified within 
a single breed, such as the FGFR3 mutation causing limb 
overgrowth in Suffolk sheep [21], and these mutations 
tend to be recessive deleterious mutations. This bias 
toward identification of recessive conditions can be ex­
plained by the relatively small effective population size of 
many domestic species. Thus, a recessive deleterious 
muta tion may drift to high frequency within a breed 
before a problem is recognized (for example, [22]). In 
contrast, an animal with a deleterious, dominant 
mutation will be immediately culled and the causal gene 
is unlikely to be investigated. For recessive mutations, 
once the syndrome is recognized an effort is made to 
discover the cause.
An alternative to the within­breed approach is to 
examine differences across breeds. This approach aims to 
identify breed­defining loci under the assumption that 
selective sweeps will be evident in the genome. Examples 
of mutations identified using across breed identification 
methods include the FGF4 mutation for disproportionate 
short stature in dogs such as the dachshund (Table  2) 
and, although the causative mutations are unknown, the 
IGF1 mutation in small dog breeds, and the PLAG1-
CHCHD7 intergenic region in Holstein­Friesian and 
Jersey cattle [23­25]. Common haplotypes for these 
mutant alleles suggest strong selection and identical 
mutations by descent, rather than selection for recurring 
new (de novo) mutations. For example, at least one copy 
of the haplotype carrying the mutant allele FGF4 
mutation is found in 19 different dog breeds with 
chondrodysplasia [24]. Similarly for IGF1, the small IGF1 
haplotype was homozygous in 23 different small dog 
breeds [23]. One problem created by these selective 
sweeps it that causative mutations are often difficult to 
isolate. Only analysis of different breeds or outbred popu­
lations, preferably where the mutation is not under 
selection, will enable the identification of the mutation by 
breaking up the observed linkage disequilibrium (LD) 
blocks. As observed in mice, the relative allelic and locus 
homogeneity found for dogs and livestock contrasts with 
the diversity observed for mutations conferring obvious 
phenotypes in humans (as listed in Table 1).
Results from livestock and companion species highlight 
that mutations with large­to­moderate effects are present 
without severe pleiotropic effects and can reach high 
frequencies in artificially selected populations. The 
PLAG1­CHCHD7 intergenic region, for example, was 
identified by Karim et al. [25] because alternative alleles 
were at high frequency in the Holstein­Friesian and 
Jersey breeds. The effect of the region is moderate, with 
homozygotes approximately ±0.4  SD from the hetero­
zygote genotypes (assuming the SD of body weight in 
cattle is about 50  kg). Similarly in dogs, the genetic 
architecture is such that ≤3 loci can explain much of the 
between­breed phenotypic variation for body weight 
[26]. This implies the presence of high frequency alleles 
with large­to­moderate effects on body size within a 
breed.
Variants with small effects
Studies in humans
GWASs for stature in humans provide one of the best 
resources for studying the segregating genetic variation 
in body size. Over 20 GWASs for human height have 
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been published and 389 genes have been associated with 
height (P < 1 × 10­5; Table S1 in Additional file 1). In con­
trast to the mutations with large effect, causative muta­
tions underlying significant associations have seldom 
been identified. The assumption is that significant SNP 
markers are in high LD with a causal mutation in a 
nearby gene. Sometimes there are difficulties in distin­
guishing between two genes near to a single marker and, 
occasionally, no known genes are located in the region. 
However, associations between SNP and height are 
highly significant, replicate in independent samples of 
people and, in some cases, in different racial groups 
(Table  S2 in Additional file  1) [27]. The genes near 
significant SNPs are not a random sample of genes 
because they are enriched for genes implicated in skeletal 
development and often they are in high LD with non­
synonymous coding mutations or known regulatory 
mutations [7].
The estimated effects from human height GWASs are 
very small (0.02 to 0.13 SD), usually additive rather than 
recessive or dominant, and have moderate minor allele 
frequency (0.01 to 0.5). The effect of the causal mutation 
could be larger than the estimated effect of the SNP and 
its minor allele frequency (MAF) lower, but the most 
parsimonious explanation is that the effect sizes and 
MAF for mutations are similar to those of the associated 
SNP. This implies that the mutations currently detected 
by GWASs are relatively common and the effect size for 
Table 2. Genes with known mutationsa affecting body size identified from domestic species, and corresponding 
conditions in humans and/or mice
Species Syndrome Gene Phenotype description Conditions in humans and/or mice References
Bos taurus Disproportionate 
chondrodysplasia 
in Japanese Brown 
cattle
EVC2 (Ellis-van Creveld 
syndrome 2)
SNP and deletion variant; 
recessive mutation
Humans: skeletal dysplasia, Ellis-van 
Creveld syndrome (OMIM 225500); 
autosomal recessive
[88,89]
Bos taurus Disproportionate 
chondrodysplasia in 
Angus cattle
PRKG2 (protein kinase, 
cGMP-dependent, 
type II)
SNP variant; recessive 
homozygotes are 15.8 
cm shorter at birth than 
wild-type; suggestion of 
embryonic lethality
Mice: homozygous null mice exhibit 
disproportionate dwarfism, and 
decreased weight and body length
[90,91]
Bos taurus Dwarfism in Dexter 
cattle
ACAN (aggrecan) Insertion variant; recessive 
lethal; heterozygotes 
show disproportionate 
chondrodysplasia
Humans: short stature and skeletal 
dysplasia (for example, OMIM 165800); 
dominant and recessive forms. Mice: 
spontaneous mutation results in 
dwarfism and skeletal abnormalities; 
recessive lethal
[92-94]
Bos indicus Dwarfism in 
Brahman cattle
GH1 (growth 
hormone 1)
SNP variant; recessive 
homozygotes are 70% of 
wild-type phenotype height 
and weight
Humans: proportionate short stature 
(for example, OMIM 173100); dominant 
and recessive forms. Mice: ENU-induced 
mutation with additive effects causing 
dwarfism
[95-97]
Canis lupus 
familiaris
Disproportionate 
chondrodysplasia 
in dogs
FGF4 (fibroblast 
growth factor 4)
SNP variant; identified by 
between-breed analyses; 
shortened limbs
Humans: involved in cancer and limb 
development. Mice: null homozygous 
mice show embryonic mortality; mice 
with conditional mutations show 
normal limb development
[24,98-100]
Sus scrofa 
domesticus
Disproportionate 
chondrodysplasia in 
Danish Landrace
COL10A1 (collagen, 
type X, alpha 1)
SNP variant; dominant 
mutation; shortened limbs
Humans: dominant mutation causes 
Schmid metaphyseal chondrodysplasia 
(OMIM 156500). Mice: dominant 
mutation shows abnormal skeletal 
growth
[101-105] 
Ovis aries Disproportionate 
chondrodysplasia in 
Suffolk sheep
FGFR3 (fibroblast 
growth factor 
receptor 3)
SNP variant; overgrowth 
of limbs; semi-lethal in 
homozygotes; cannon 
bone length +1 cm in 
heterozygotes; recessive 
but speculated co-
dominance
Humans: associated with 13 
phenotypes, including dwarfing 
syndromes and cancer (for example, 
OMIM 100800). Mice: homozygous 
null mice show abnormal skeletal 
development, decreased growth and 
premature death; mild symptoms in 
heterozygotes
[21, 87]
aData obtained from Online Mendelian Inheritance in Animals [106], Mouse Genome Informatics [17] and Online Mendelian Inheritance in Man [107]. ENU, N-ethyl-N-
nitrosourea.
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these mutations is small. However, the SNPs identified by 
GWASs explain only a small proportion (approximately 
12%) of the known inherited variation for stature [7]. This 
has caused much debate among geneticists (Box 1). If the 
180 loci identified by Lango Allen et al. [7] explain 12% of 
the genetic variation, then this implies a minimum of 
1,500 loci to explain the segregating genetic variance for 
stature in human populations (that is, 180/0.12 = 1,500). 
This number is the minimum expected because loci 
identified by Lango Allen et al. are presumably a subset 
of loci with the largest influence on the genetic variance.
The genes implicated in the GWASs are sometimes the 
same genes identified with large effect mutations for 
height (Table 3) [7]. Therefore, genes may have mutations 
causing both large and small effects on stature [27], 
highlighting that there may be multiple alleles at a locus. 
Multiple alleles have the effect of reducing power to 
detect loci through GWASs. This is because each muta­
tion is likely to be in LD with a different nearby SNP and 
the frequency of mutations is likely to reduce as number 
of segregating alleles increases. Allelic hetero geneity may 
explain why some of the genes with large effect mutations 
for height (for example, FBN1, as listed in Table  1) are 
not identified by GWASs. Allelic hetero geneity is not an 
important factor for detection in family­based studies 
because mutations are identical­by­descent within a 
family.
Studies in non-human mammals
Generally, GWASs in domestic species explain a much 
higher percentage of the genetic variance than human 
GWASs [28]. In mice, for example, the study by Valdar et 
al. [29] explains an average of 75% of the genetic variance 
in 97 traits, including body weight. GWASs in mice are 
not performed with a wild population but with a hetero­
geneous population derived from inbred strains. These 
heterogeneous strains show LD over long genomic 
distances and this probably explains why a higher 
proportion of variance is captured. In addition, Valdar et 
al. assign an identical­by­decent probability to each 
marker [29]. This may track the causal polymorphisms 
from each strain better than the use of individual SNPs 
because, for example, Valdar et al. [29] also show that 
diallelic markers (that is, SNPs) cannot account for the 
described loci in a third of cases.
A further consequence of LD over long distances is that 
positioning the causal polymorphism can be very difficult 
from GWASs in model species. This is similar to the 
problem encountered for breed­defining loci in dogs, for 
example; however, loci identified from GWASs are 
segregating variants causing within­population variation 
in body size. In the study of Valdar et al. [29], quantitative 
trait loci regions for body weight contain up to 22 genes 
within the 50% confidence interval. It is likely that some 
of these regions contain multiple causal polymorphisms, 
particularly for regions that show differences between the 
identical­by­descent and diallelic results.
Association studies in livestock generally have small 
sample sizes (approximately 2,000 records), and hence 
relatively high false discovery rates compared with 
GWASs in humans (for example, [30]). This means that 
defining genes identified by livestock GWASs is more 
uncertain than those identified in humans. However, 
Pryce et al. [31] tested 55 genes that had previously been 
identified in human GWASs for affects on stature in dairy 
and beef cattle [31]. A total of eight genomic regions with 
ten genes (Table 2; Table S2 in Additional file 1) showed 
significant associations (P < 1 × 10­3). This confirms that 
real causal mutations are being detected by human 
GWASs, and highlights that mutations in the same genes 
Box 1. The case of the missing heritability
The inability of genome-wide association studies (GWASs) to 
explain most of the known inherited variation in complex traits 
(including human height) has caused much debate (for example, 
[33]). For instance, Lango Allen et al. [7] used >100,000 people 
to find 180 SNPs significantly associated with height. When 
the effects of these SNPs were estimated in an independent 
sample, they explained only 10% of the phenotypic variance 
although the heritability of height is approximately 80%. So why 
do we not detect these missing variants? Part of the reason for 
the difference between 80% and 10% is that the experiment 
lacked power to find SNPs with small effects despite the large 
sample size [27]. Lango Allen et al. [7] estimate the power to find 
associations of the size they discovered (0.02 to 0.13 standard 
deviation (SD) units) and suggest that there would be 700 loci 
with effect sizes in this range that would collectively explain 16% 
of the phenotypic variance. In contrast, Yang et al. [34] estimate 
that 45% of the phenotypic variance could be explained by 
all the SNPs together when the significance level of individual 
markers is ignored. The difference between 16% and 45% is 
because SNPs with real associations with height had an effect 
that was too small to be detected by Lango Allen et al. This 
group of SNPs could include two classes of mutations, one with 
very small effects (<0.02 SD) and another with small (0.02 to 
0.13 SD) or intermediate (0.1 to 1 SD) effects but in low linkage 
disequilibrium (LD) with many SNPs. Under these conditions, the 
analysis of Lango Allen et al. may underestimate the number of 
mutations with small effects, because if mutations are associated 
with several SNPs the effect of any one SNP may be too small 
to be significant in a GWAS. However, the collective variance 
explained by all associated SNPs is included in the analysis of 
Yang et al. [34]. The difference between 45% and 80% is likely 
to be caused by imperfect LD between the SNP and the causal 
mutations. That is, even when multiple SNPs track a mutation they 
may not completely explain variance at the loci. This lack of perfect 
LD could be due to the causal polymorphisms having a low 
frequency (for example, a minor allele frequency <0.1). We suggest 
that some of these loci could be the missing intermediate effect 
mutations highlighted by Figure 2.
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Table 3. Genes identified with both large and small-effect mutations that affect stature and skeletal formation in humans
 OMIM phenotypes GWASs identifying 
 associated with the gene  the gene 
Gene Number Example stature phenotypea Number Reference(s)
ACAN (aggrecan) 3 Spondyloepimetaphyseal dysplasia, aggrecan type (-)  4  [7,108-110]
  (OMIM 612813)
ADAMTS10 (ADAM metallopeptidase with  1 Weill-Marchesani syndrome 1, recessive (-) (OMIM 277600) 2 [109,111]
thrombospondin type 1 motif, 10)
ARSE (arylsulfatase E) (chondrodysplasia punctata 1) 1 Chondrodysplasia punctata, X-linked recessive (-) (OMIM 302950) 2 [110,112]
BBS1 (Bardet-Biedl syndrome 1) 1 Bardet-Biedl syndrome 1 (-) (OMIM 209900) 1 [109]
BBS7 (Bardet-Biedl syndrome 7) 1 Bardet-Biedl syndrome 7 (-) (OMIM 209900)  1 [109]
BRCA2 (breast cancer 2, early onset) 9 Fanconi anemia, complementation group D1 (-) (OMIM 605724) 1 [7]
COL11A1 (collagen, type XI, alpha 1) 4 Fibrochondrogenesis (-) (OMIM 228520) 1 [113] 
CYP19A1 (cytochrome P450, family 19, subfamily A,  2 Aromatase deficiency (-) (OMIM 613546) 3 [7,109,114]
polypeptide 1)
DYM (dymeclin) 2 Smith-McCort dysplasia (-) (OMIM 607326) 4 [7,108,
    109,112]
EIF2AK3 (eukaryotic translation initiation factor  1 Wolcott-Rallison syndrome (-) (OMIM 226980) 2 [7,109]
20alpha kinase 3)
EXT1 (exostosin 1) 2 Exostoses, multiple, type 1 (-) (OMIM 133700) 1 [115]
FANCC (Fanconi anemia, complementation group C) 1 Franconi anemia, complementation group C (-) (OMIM 227645) 1 [7]
FANCE (Fanconi anemia, complementation group E) 1 Franconi anemia, complementation group E (-) (OMIM 600901) 1 [7]
FBN2 (fibrillin 2) 1 Contractural arachnodactyly, congenital (+) (OMIM 121050) 1 [110]
FGFR3 (fibroblast growth factor receptor 2) 13 Achondroplasia (-) (Table 1) 1 [7]
FLNB (fibamin B, beta) 5 Larsen syndrome (-) (OMIM 150250) 1 [116]
GALNS (galactosamine (N-acetyl)-6-sulfate sulfatase) 1 Mucopolysaccharidosis IVA (-) (OMIM 253000) 1 [7]
GDF5 (growth differentiation factor 5) 8 Acromesomelic dysplasia, Hunter-Thompson type (-) (OMIM 201250) 1 [7]
GH1 (growth hormone 1) 4 Growth hormone deficiency, isolated, type IA (-) (OMIM 262400) 1 [109]
GHR (growth hormone receptor) 4 Laron dwarfism (-) (OMIM 262500) 1 [109]
GHSR (growth hormone secretagogue receptor) 1 Short stature (-) (OMIM 604271) 2 [7,109]
HMGA2 (high-mobility group AT-hook 2) 1 Leiomyoma, uterine, somaticb (-) (OMIM 150699) 9e [7,10-112,
    114,117,118]
IHH (Indian hedgehog) 2 Acrocapitofemoral dysplasia (-) (OMIM 607778) 2 [7,111]
KCNJ2 (potassium inwardly-rectifying channel,  3 Atrial fibrillation, familial, 9 (-) (OMIM 613980) 1 [7]
subfamily J, member 2)
PTCH1 (patched 1) 3 Basal cell nevus syndromec (-) (OMIM 109400) 3e [7,108-109,
    119,120]
RNF135 (ring finger protein 135) 1 Macrocephaly, macrosomia, facial dysmorphism syndrome (+)  1 [7]
  (OMIM 614192)
RPL5 (ribosomal protein L5) 1 Diamond-Blackfan anemia 6d (-) (OMIM 612561) 1 [7]
RUNX2 (runt-related transcription factor 2) 2 Cleidocranial dysplasia (-) (OMIM 119600) 1 [7]
SLC39A13 (solute carrier family 39 (zinc transporter),  1 Spondylocheirodysplasia, Ehlers-Danlos syndrome-like (-)  1 [7]
member 13)  (OMIM 612350)
TBX15 (T-box 15) 1 Cousin syndrome (-) (OMIM 260660) 2 [108,121]
Genes with mutation of large effect are from the 241 genes identified by Lango Allen et al. [7] from the Online Mendelian Inheritance in Man database. Surveyed 
genome-wide association studies are listed in Table S1 in Additional file 1.
aThe effect of the mutation on stature phenotypes indicate reduced (-) or increased (+) height for carriers of the mutation; bmutation identified for uterine 
leiomyomata associated with 1.5 cm decrease in height (that is, 0.21 standard deviation (SD) units, assuming SD for height is 7 cm) [121, 122]; cheterogeneous 
condition causing skeletal abnormalities and predisposition to tumors, and there is one report of PTCH1 duplication causing microcephaly [120]; dDiamond-Blackfan 
anemia is a genetically heterogeneous condition causing growth failure and RPL5 is associated with the disease; evalidated gene in cattle [31].
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contribute to segregating variation for both human and 
cattle populations. This implies that mutations in these 
genes may occur without obvious pleiotropic effects.
Finally, divergent selection experiments in domestic 
species support a model of many loci affecting body size. 
For example, selection experiments over many genera­
tions in cattle and mice have produced phenotypes that 
are outside the normal range of the base population 
(Figure 1). MacArthur [32] shows a difference of 10.9 SD 
between small and large body size mice after 21 
generations of selection. The selection response implies 
at least dozens of genes affecting the trait, but it is 
impossible to distinguish between dozens and thousands 
of loci. If we assume the same effect size as the largest 
effects in human GWASs (that is <0.1 SD), this response 
would require at least 54 genes to explain the divergence 
of the lines (that is, 10.9/(2 × 0.1) = 54 genes).
Where are the intermediate effects?
The allele frequencies and mutation effect for the com­
bined results from GWASs for human height and within 
family studies are shown in Figure 2. This highlights the 
disjointed nature of the datasets. At one extreme, rare 
variants with large effects (>2  SD) have been mapped 
using within­family segregation of markers and pheno­
types. At the other extreme, there are mutations segre­
gating at intermediate frequencies within popula tions 
that have been identified by GWASs (0.02 to 0.13  SD). 
But what has happened to the mutations with the 
intermediate effects? Studies in model organisms such as 
Drosophila suggest a continuous J­shaped distribution of 
effects on complex traits, where there are many loci of 
small and intermediate effects and few loci of larger effect 
[28]. In livestock and domestic species, loci with inter­
mediate effects are also occasionally observed.
One explanation is that the intermediate effects are not 
efficiently detected in humans because of the current 
detection methodologies. This is because family­based 
studies detect only extreme phenotypes, whereas 
association studies usually detect only rare, large effect 
mutations and segregating mutations in high LD with 
SNPs at moderate allele frequencies. The power of 
GWASs to detect a mutation depends on both the 
variance explained by the mutation (that is, 2pqa2, where 
p is the allele frequency, p + q = 1, and a is the effect size) 
and the LD between the mutation and SNP. Therefore, 
mutations with intermediate effect but frequencies lower 
than common SNPs are unlikely to be detected because of 
the small variance explained by the locus and also because 
of weak LD with common SNPs. Loci with inter mediate 
effects and poor LD with common SNPs may also explain 
some of the so­called ‘missing heritability’ (Box 1).
Mutations with intermediate effects might be detected 
as follows. (1)  In populations subject to strong, recent 
artificial or natural selection, alleles that were previously 
rare can be driven to intermediate frequency where they 
are easier to detect; the PLAG1-CHCHD7 polymorphism 
in cattle may be an example of this. (2)  Identical­by­
descent haplotypes may be in complete LD with a rare 
mutation even though it is not in complete LD with any 
single SNP (for example, [29]). (3)  Genomic sequence 
should include the causal mutations so that imperfect LD 
is not a problem. However, the power to detect a 
mutation is still determined by the variance it explains 
(that is, 2pqa2) such that large sample sizes will still be 
necessary to detect variants explaining small proportions 
of the phenotypic variance.
Understanding the observed distribution of effects 
for human stature
The genetic architecture that we observe in populations 
today is the result of evolutionary processes. Mutation 
Figure 1. Selection experiments with domestic species indicate 
many genes underlie variation in body size. (a) Angus cattle [35] 
and (b) mice [36] from long-term selection experiments for high 
and low growth show phenotypes outside the normal range of the 
unselected population. The photographs were kindly supplied by 
Robert Herd (NSW Department of Primary Industries, NSW, Australia) 
and Lutz Bünger (University of Edinburgh, Edinburgh, UK). Please 
note that the photographs used within this figure are permitted to 
be used only within this publication.
(a)
(b)
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creates new variants and then selection and genetic drift 
determine the observed allele frequency. Not all muta­
tions affect stature, but the results reviewed here suggest 
that there are many sites in the genome where mutation 
does affect size. Mutations in 241 genes are known to 
cause large effects on stature and skeletal features in 
humans. In many cases, >20 alleles at a gene with a large 
effect have been discovered and presumably not all 
possible sites in these genes have been discovered. 
Assuming there are 50 sites at 250 genes, this implies that 
there are 12,500 sites where mutations have a large effect 
(>2 SD). This is likely to be an underestimate because we 
previously estimated that there are 2,500 sites where 
mutation can cause Marfan syndrome alone.
The mutations of large effect are subject to strong 
selection, presumably due to their pleiotropic effects on 
fitness. This is shown by the high rate of de novo muta­
tions among people carrying a mutant allele (Table  1). 
The selection coefficient is equal to the proportion of 
mutant alleles that are new mutations because an equal 
number of mutant alleles must be eliminated each 
generation. Disorders vary, but 25% de novo mutation 
rates are not uncommon (Table 1). Assuming a per gene 
mutation rate of 5 × 10­7 (50 sites and a mutation rate of 
1  ×  10­8 per site), the equilibrium allele frequency for 
muta tions at such a locus is 5 × 10­7/0.25 = 2 × 10­6 (or a 
prevalence of approximately 1 in 500,000). Genes where 
mutations occur at much higher frequencies, such as 10­4 
(or 1 in 10,000), must be due to higher mutation rates, a 
lower selection coefficient, genetic drift, or they may be 
recessive. Even at a frequency of 10­4,  a mutation with 
effect of 2 SD explains only 8  ×  10­4 of the phenotypic 
variance (for details see Additional file 1). However, the 
average frequency rate for all mutations is much less than 
10­4. If we assume the average frequency is 1 × 10­5, the 
variance explained per locus is 8  ×  10­5 and the total 
variance explained for all mutations is 0.025 of the total 
phenotypic variance. Considering that 0.8 of the 
phenotypic variance is due to inherited genetic factors, 
we conclude that most of the genetic variance is not due 
to mutations of large effect.
It seems likely that other mutations at these 250 genes 
can cause smaller effects on height and experimental 
results support this assertion [7]. Lango Allen et al. [7] 
discovered 180 loci for height in humans that were 
estimated to explain about 10% of the phenotypic 
variance. When they allowed for the lack of power of 
their experiment, they concluded there were 700 loci 
associated with height but these would still only explain 
16% of the variance. Therefore, 700 is likely to be a 
considerable underestimate. As stated previously, mouse 
knockout experiments suggest 6,000 genes can affect 
height [18]. If there are 50 sites within a gene where 
mutation has a large effect, there are likely to be many 
more, including sites regulating gene expression, with 
small effects. If we assume 6,000 genes each with 200 
sites, there are 1,200,000 mutable sites that affect height.
GWASs find SNPs with effects <0.13  SD. Even new 
mutations at a possible 1.2 million sites, a mutation rate 
of 10­8 per site and an average effect per mutation of 
0.1 SD would only add 2.4 × 10­4 to the genetic variance 
each generation (for details see Additional file  1). This 
mutation variance would need to accumulate for 3,300 
generations to account for the known heritability. This 
implies that selection against these mutations of small 
effect is weak.
The selection pressure against mutations probably 
decreases as the size of the effect on height decreases. 
Mutations with very small effects may be effectively 
neutral in the human population and drift in allele 
frequency until they are lost or fixed by chance. Other 
mutations with intermediate effect will also drift in 
Figure 2. Mutations with intermediate effect (0.1 to 1 SD units) and low frequency (0.01 to 0.001) are not detected efficiently by either linkage or 
genome-wide association studies. Shown are the allele effect size (x-axis) and frequency (y-axis) for GWAS results from Lango Allen et al. [7] and for 
the sample of mutations described in Table 1. Assumptions for frequencies and effect of mutations from Table 1 are noted in the table footer.
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frequency but selection (due to pleiotropic effects) will 
cause most to have a low frequency. It is these mutations 
of intermediate and small effect that appear to explain 
most of the genetic variance. Although the mutations of 
intermediate effect are poorly detected by current 
experiments because they are not in strong LD with SNPs 
used in GWASs, we know they are biologically plausible 
because we occasionally detect such mutations in 
domestic animals when artificial selection or genetic drift 
caused by inbreeding causes their frequency to increase.
Conclusions
In summary, we have surveyed the current known 
mutations affecting body size in humans, mice, dogs and 
livestock species. Although mutations of intermediate 
effect are poorly detected by current experiments in 
humans, we know they are biologically plausible because 
we occasionally detect such mutations in domestic 
animals when artificial selection or genetic drift increases 
their frequency, and enables their detection. We see that 
genomic information is gradually building a model for 
genetic architecture implying many thousands of discrete 
genes, each with many mutable sites and (possible) 
segregating mutations. The frequency and size of effect 
for mutations differs between populations where natural 
selection and recent history play significant roles in 
determining the observed distribution. We see extensive 
(detrimental) pleiotropy for large­effect mutations for 
rare conditions in humans and also occasionally in 
livestock. Mutations with less obvious pleiotropy and 
more modest effects are observed in domestic popu la­
tions because of selection and drift, but this class of 
mutations is rarely observed in humans. Mutations with 
very small effects occur at intermediate frequencies in 
both humans and livestock. However, the current data 
are limited because associations of phenotype are with 
genetic markers (that is, SNP) and not causal mutations.
In the future, genomic sequence data will offer the 
opportunity to discover the causal mutations underlying 
quantitative traits such as body size. Of key interest are 
the number, effect size and frequency of such mutations. 
It remains to be seen, for example, if the missing 
intermediate effect size mutations for human height are 
identified from genomic sequence and if these mutations 
will further explain some of the ‘missing heritability’. It is 
likely that body size, as a model trait, will continue to 
inform and direct research into the future.
Additional files
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